VILON
Vilon (Lys-Glu) is supplied as one of the short Khavinson bioregulator peptides, studied for gene-expression and cell-signaling pathway research. Supplied strictly for laboratory and educational research. Not for human or veterinary use.
Vial amount
Purchase option
Checkout includes a research-use attestation. Materials are supplied only for laboratory and educational research.
VILON in research
Vilon (Lys-Glu) is supplied as one of the short Khavinson bioregulator peptides, studied for gene-expression and cell-signaling pathway research.
General RUO catalog item for documented laboratory workflows.
Bench context
Supplied as a research-grade reference material for documented laboratory and educational research workflows.
Available amounts
Select from the stocked vial amounts for VILON before adding the material to cart.
Claims discipline
No protocol instructions, no dosing, no medical advice, and no therapeutic or human-use promises.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, not for diagnostic or therapeutic use, not a drug or supplement.
No supplier listing text is on file yet for this item.
The full research picture, clearly labeled
BioRegen reports the entire research landscape for this compound across four clearly separated tiers, strongest evidence first. Lower tiers, including community and anecdotal reports, are labeled as such and are not BioRegen claims.
Independent, peer-reviewed human trial evidence for Vilon (Lys-Glu) is minimal. The bulk of reported human-relevant work comes from a small body of Russian gerontology and immunology literature associated with the Khavinson (St. Petersburg) bioregulator school, where investigators have described immune and aging-related endpoints; this work has had limited independent replication outside those groups. No large, multi-center, placebo-controlled trials registered with major Western registries are established for this compound. Readers should treat the available human-tier evidence as preliminary and not independently confirmed.
Most of the published research on Vilon sits at the preclinical tier, reported largely in laboratory and animal studies from Russian research groups. These investigators have described effects in rodent models on parameters such as immune-cell activity, thymus-related function, and markers studied in the context of aging. As with much single-school preclinical work, independent cross-laboratory confirmation in Western literature is limited, so these findings are best read as exploratory laboratory and animal research rather than settled biology.
Within longevity and biohacker communities, and in some niche anti-aging media coverage, short peptide bioregulators in this class are occasionally discussed alongside other Khavinson-school peptides. Such discussion typically references the Russian research narrative rather than independent human data, and individual accounts vary widely. This material is unverified anecdotal commentary, not controlled data, and not a BioRegen claim.
Vilon (Lys-Glu) is not an approved drug with the U.S. Food and Drug Administration, the European Medicines Agency, or comparable major regulators, and it carries no recognized approval for the prevention or treatment of any condition. Its history is rooted in research settings rather than registered pharmaceutical approval. BioRegen supplies it strictly for laboratory and educational research, not for human use.
Tiers are evidence categories, not endorsements. Clinical and preclinical entries summarize third-party published research. Community and anecdotal entries are unverified reports discussed by others, not findings and not BioRegen claims. Nothing here is medical advice, and no compound is approved for human or veterinary use except where explicitly stated under Regulatory status.
What the published research says about VILON
This section reports on published research referenced in BioRegen's own research library. It is not a claim by BioRegen that the compound provides any benefit, and nothing here is medical advice.
- [1] Caputi S, et al. (2019). Effect of short peptides on neuronal differentiation of stem cells. Int J Immunopathol Pharmacol. doi:10.1177/2058738419828613
- [2] Ashapkin V, et al. (2020). Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Mol Biol Rep. doi:10.1007/s11033-020-05506-3